Updated Jul 16, 2026 · Last SEC filing 2026-05-05
Terns Pharmaceuticals, Inc. (TERN) has filed 9 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-05-05. 2 Form 8-K material event filings were reported by TERN in the last 90 days. InsiderAlpha tracks every TERN SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0001831363 |
| Form 4 filings (90d) | 9 |
|---|---|
| Form 8-K filings (90d) | 2 |
| Latest Form 4 filing | 2026-05-05 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Burroughs Amy L. | Chief Executive Officer | J — Other acquisition / disposition | 146.6K | $53.00 | $7.77M | SEC | |
| Gengos Andrew | Chief Financial Officer | J — Other acquisition / disposition | 40.5K | $53.00 | $2.15M | SEC | |
| Burroughs Amy L. | Chief Executive Officer | D — Derivative transaction | 150.0K | $53.00 | $7.95M | SEC | |
| Gengos Andrew | Chief Financial Officer | D — Derivative transaction | 68.8K | $53.00 | $3.64M | SEC | |
| Kuriakose Emil | Chief Medical Officer | J — Other acquisition / disposition | 24.6K | $53.00 | $1.30M | SEC | |
| Kuriakose Emil | Chief Medical Officer | D — Derivative transaction | 82.0K | $53.00 | $4.34M | SEC | |
| Burroughs Amy L. | Chief Executive Officer | J — Other acquisition / disposition | 8.3K | $53.00 | $441K | SEC | |
| Kuriakose Emil | Chief Medical Officer | S — Open-market sale | 942 | $52.75 | $50K | SEC | |
| Burroughs Amy L. | Chief Executive Officer | M — Option exercise [10b5-1] | 14.6K | $4.64 | $68K | SEC | |
| Burroughs Amy L. | Chief Executive Officer | S — Open-market sale [10b5-1] | 11.8K | $46.57 | $550K | SEC | |
| Burroughs Amy L. | Chief Executive Officer | S — Open-market sale [10b5-1] | 2.8K | $47.30 | $131K | SEC | |
| Burroughs Amy L. | Chief Executive Officer | S — Open-market sale [10b5-1] | 4.1K | $39.80 | $163K | SEC | |
| Burroughs Amy L. | Chief Executive Officer | M — Option exercise [10b5-1] | 14.6K | $4.64 | $68K | SEC | |
| Burroughs Amy L. | Chief Executive Officer | S — Open-market sale [10b5-1] | 8.2K | $39.22 | $320K | SEC | |
| Burroughs Amy L. | Chief Executive Officer | S — Open-market sale [10b5-1] | 2.3K | $38.07 | $89K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Terns Pharmaceuticals, Inc. (TERN). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| KINDLER JEFFREY B | 9 | — |
| FELLOWS DAVID A | 9 | — |
| Tripuraneni Radhika | 7 | — |
| Kuriakose Emil | 7 | $5.65M |
| Quigley Jill M. | 7 | — |
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in TERN insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live TERN dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.